Century Therapeutics/IPSC

$4.61

-1.91%
-
1D1W1MYTD1YMAX

About Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-104 is a multi-specific collaboration program for acute myeloid leukemia.
Ticker
IPSC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Brent Pfeiffenberger
Employees
163
Headquarters
Philadelphia, United States

IPSC Metrics

BasicAdvanced
$281.22M
Market cap
-
P/E ratio
-$2.19
EPS
-
Beta
-
Dividend rate

What the Analysts think about IPSC

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
218.22% upside
High $22.00
Low $10.00
$4.61
Current price
$14.67
Average price target

IPSC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-32,700% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
∞%
Net income
$-32.7M
-1.51%
Profit margin
-32,700%
-∞%

IPSC Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.3%
QuarterlyAnnual
Q3 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.53
-$0.53
-$0.56
-$0.55
-
Expected
-$0.59
-$0.52
-$0.54
-$0.51
-$0.55
Surprise
-10.91%
1.25%
2.89%
7.3%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Century Therapeutics stock

Buy or sell Century Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing